CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratiory syncytial virus, rotavirus, malaria, and universal influenza. The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck. The company was founded in 2000 and is headquartered in Tübingen, Germany.
Harga semasa 5CV.STU ialah €3.35 EUR — telah meningkat sebanyak +0% dalam 24 jam yang lalu. Pantau prestasi harga saham CureVac N.V. dengan lebih dekat pada carta.
Apakah simbol saham CureVac N.V.?▼
Bergantung pada bursa, simbol saham mungkin berbeza. Sebagai contoh, di bursa Boerse Stuttgart, saham CureVac N.V. didagangkan di bawah simbol 5CV.STU.
Berapa ramai pekerja yang dimiliki oleh CureVac N.V.?▼
Sehingga Julai 13, 2026, syarikat mempunyai 764 pekerja.
CureVac N.V. terletak dalam sektor apa?▼
CureVac N.V. beroperasi dalam sektor Kesihatan & Kesejahteraan.
Bilakah CureVac N.V. menyiapkan split saham?▼
CureVac N.V. tidak mempunyai sebarang split baru-baru ini.
Di manakah ibu pejabat CureVac N.V.?▼
Ibu pejabat CureVac N.V. terletak di Tübingen, Jerman.